News

Article

Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T

Author(s):

Fact checked by:

Key Takeaways

  • John Sykes, guitarist for Thin Lizzy and Whitesnake, died at 65 after battling cancer, leaving a legacy of musical talent and charisma.
  • Mike Peters is undergoing CAR-T cell therapy for Richter’s Syndrome, following a history of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
SHOW MORE

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

An image of a doctor taking notes.

Here is this week’s cancer news.

Whitesnake, Thin Lizzy Guitarist John Sykes Died of Cancer

John Sykes, a guitarist known for his work with Thin Lizzy and Whitesnake, has died. The announcement, posted to Sykes’ official Facebook page on Jan. 20, 2025, said he died after a “hard-fought battle with cancer,” but it did not specify what type of cancer Sykes had when he died.

Sykes, according to a post on his official website, died in 2024, and the BBC reported he was 65.

The guitarist joined Thin Lizzy in 1982, and then became part of Whitesnake in 1984, the BBC reported, with Sykes eventually recording two albums with the latter band.

Sykes’ time in Whitesnake included the band’s 1987 self-titled album featuring a pair of hit singles co-written by Sykes, “Is This Love” and “Still of the Night.”

“It is with great sorrow we share that John Sykes has passed away after a hard-fought battle with cancer,” read the statement on Sykes’ website. “He will be remembered by many as a man with exceptional musical talent but for those who didn’t know him personally, he was a thoughtful, kind and charismatic man whose presence lit up the room.”

Mike Peters Beginning CAR-T Cell Therapy for Richter’s Syndrome

Mike Peters, frontman for Welsh hit-making rockers The Alarm, is set to begin CAR-T cell therapy treatment for Richter’s Syndrome, according to a report from the BBC.

About Richter’s Syndrome

According to The Leukemia and Lymphoma Society, for 2% to 10% of patients with CLL, the disease will transform into something more complex.

“Of this small group, 95% may develop diffuse large-B cell lymphoma, and the other 5% may develop Hodgkin lymphoma. This is known as ‘Richter transformation’ or ‘Richter’s syndrome,’” The Leukemia and Lymphoma Society explains on its website.

Peters, 65, received a diagnosis of Richter’s Syndrome, described by the BBC as an aggressive lymphoma, in April 2024. He had previously received a diagnosis of non-Hodgkin lymphoma in 1995, then chronic lymphocytic leukemia (CLL) in 2005, followed by relapses of CLL in 2015 and 2022.

CAR-T cell therapy, according to the National Cancer Institute, is a type of treatment where a patient’s own T cells, a part of the immune system taken from a patient’s blood, are changed in a laboratory so that they will learn to attack cancer cells.

“My white lymphocytes were harvested in December. Those were then sent to a laboratory where each blood cell was re-engineered by scientists and then targeted to seek and destroy the Richter's Syndrome," Peters said, according to the BBC.

Former Planned Parenthood Leader and Activist Cecile Richards Died

Cecile Richards, the former longtime president of Planned Parenthood and an activist for abortion access and women’s rights, died on Jan. 20, 2025, at the age of 67, the Associated Press has reported.

Richards, according to the Associated Press, had been diagnosed with the aggressive form of brain cancer glioblastoma in 2023, five years after the end of her 12-year tenure as the leader of Planned Parenthood.

Before her time at Planned Parenthood, she was the deputy chief of staff for House Democratic Leader Nancy Pelosi. Pelosi, in a statement, said, “It was my privilege to work directly with Cecile for many years and to have a front-row seat to her sharp intellect, strategic thinking and relentless effectiveness. As she ascended to other leadership roles, we never stopped working together to defend the rights of women and working families,” according to the Associated Press.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with short brown hair, wearing glasses.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a suit with a red bowtie.
Image of a woman with glasses and dark hair.
A panel of 3 experts on CML
Related Content